Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition

PHASE1TerminatedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy Volunteers
Interventions
DRUG

CG100649 (2 mg)

CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

DRUG

Celecoxib

Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)

DRUG

Placebo capsules

Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)

DRUG

Naproxen

Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)

DRUG

Acetazolamide

Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)

DRUG

CG100649 (8 mg)

CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).

Trial Locations (1)

19104

Institute for Translational Medicine and Therapeutics (ITMAT), University of Pennsylvania School of Medicine, Philadelphia

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CrystalGenomics, Inc.

INDUSTRY

lead

University of Pennsylvania

OTHER